Sun Pharma’s Ilumya gets FDA approval
The Food and Drug Administration has approved Sun Pharma’s Ilumya (tildrakizumab-asmn). The biologic drug is indicated to treat moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
“With the approval of Ilumya and our long-standing commitment in dermatology, we are focused on making a difference for people living with moderate-to-severe plaque psoriasis,” Sun Pharma president and CEO, North America, Abhay Gandhi said. “We are committed to working with all relevant stakeholders to make Ilumya available to appropriate people with plaque psoriasis.”
Ilumya is meant to be administered in a 100-mg dose every 12 weeks after two intial doses four weeks apart.
West-Ward launches first Norvir generic
West-Ward Pharmaceuticals, the U.S. subsidiary of Hikma Pharmaceuticals, has introduced the first generic of Norvir (ritonavir) tablets. The company’s generic treatment for HIV in combination with other antiretroviral agents will be entitled to 180 days of market exclusivity, West-Ward said.
“We are very excited to be launching ritonavir tablets,” Hikma generics president Brian Hoffman said. “This is an exciting product which demonstrates the successful execution of our strategy to develop differentiated products. We will be launching ritonavir with additional patient support and co-pay assistance to ensure more people are able to access this life-saving medicine.”
West-Ward said that as part of the launch, it was engaging advocacy organizations to gain an understanding of the best way to support patients and providers. It also will launch an education and awareness campaign that includes a website and direct communication.
West-Ward’s generic Norvir will be available in 100-mg dosage strength. The generic Norvir is launching into a market that IQVIA data said saw $208.5 million in sales for the 12 months ended December 2017.
Former Lilly CFO to head CVS Caremark
CVS Health’s pharmacy benefits manager division CVS Caremark has new leadership. The Woonsocket, R.I.-based company named Derica Rice, most recently Eli Lilly’s CFO, to the role of CVS Caremark president, effective March 30.
In his role at CVS Health, Rice will oversee the PBM business, including operations, mail service pharmacy, specialty pharmacy and sales and account management. He also will focus on pushing the PBM’s strategy by maintaining client relationships and developing new business.
“Our PBM clients and the members they serve are asking for innovation, especially around value-based reimbursement models and the role pharmacy can play in improving health outcomes and lowering total health care costs,” CVS Health COO Jon Roberts said. “We believe Derica is a great addition to our team, and the experience he brings with regard to innovation in these value-based models, in particular, will help us continue to serve our clients’ needs while also developing and delivering innovative solutions and offerings.”
Rice joins the company as CVS Health pursues its $69 billion acquisition of health insurer Aetna, and as companies increasingly look to PBM-based solutions to curb rising healthcare spend. Rice had been with Lilly since 1990 when he retired from the CFO post in December 2017. In his 27 years there, he worked his way up the ladder through various finance and operations roles. He was named CFO in 2006.